Cargando…
Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
Hepatitis C infection is one of the main reasons for liver cirrhosis and hepatocellular carcinoma. In recent years, more and more is being heard about extrahepatic manifestations of the hepatitis C infection including its possible influence on the development of hypertension and cardiovascular disea...
Autores principales: | Rajewski, Paweł, Zarębska-Michaluk, Dorota, Janczewska, Ewa, Gietka, Andrzej, Mazur, Włodzimierz, Tudrujek-Zdunek, Magdalena, Tomasiewicz, Krzysztof, Belica-Wdowik, Teresa, Baka-Ćwierz, Barbara, Dybowska, Dorota, Halota, Waldemar, Lorenc, Beata, Sitko, Marek, Garlicki, Aleksander, Berak, Hanna, Horban, Andrzej, Orłowska, Iwona, Simon, Krzysztof, Socha, Łukasz, Wawrzynowicz-Syczewska, Marta, Jaroszewicz, Jerzy, Deroń, Zbigniew, Czauż-Andrzejuk, Agnieszka, Citko, Jolanta, Krygier, Rafał, Piekarska, Anna, Laurans, Łukasz, Dobracki, Witold, Białkowska, Jolanta, Tronina, Olga, Wietlicka-Piszcz, Magdalena, Pawłowska, Małgorzata, Flisiak, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456581/ https://www.ncbi.nlm.nih.gov/pubmed/36079122 http://dx.doi.org/10.3390/jcm11175193 |
Ejemplares similares
-
HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022) -
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018) -
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021) -
Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019) -
Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)